The growth in pharma markets in emerging countries has outpaced the overall growth of the global pharma market. The growth in these markets is being driven by rapidly growing economies of these countries, increasing per capita income, increasing prevalence of lifestyle diseases, and low-cost factors. In 2008, pharma market in E7 countries (Brazil, Russia, China, India, Turkey, Mexico and Indonesia) was estimated at around US$ 96 Billion, and it is expected that high growth in these markets will help these countries increase their share in global pharma market.
According to our new research study on the sector titled “Emerging Pharmaceutical Markets Globally”, the pharmaceutical market in the above mentioned emerging countries is projected to grow at a CAGR of around 14.7% during 2009-2012. Currently, these markets are characterized by rapid urbanization, which has led to the growth in prevalence of lifestyle diseases.
Our report has found that China has the largest pharma market out of these seven countries, followed by Brazil, Mexico and India. However, the maximum growth in future is expected to be in Russia and China due to strong government support. Besides, we have identified that most of the E7 pharmaceutical markets are still dominated by acute therapies, but the growth rate of chronic therapies far exceeds that of acute therapies. Thus, the therapy mix of the market in the next few years will be much different from what it is today.
The research study provides extensive and coherent information about pharma markets in emerging countries. It highlights several emerging opportunities growing in line with development of pharma markets in E7 countries. The research study gives detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains all the key details that will help clients to draw up market strategies and assess opportunity areas for their success in these emerging pharma markets.
